Mirabegron is a beta-3 adrenergic agonist used to treat overactive bladder and neurogenic detrusor overactivity. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as solifenacin and darifenacin, it lacks significant antimuscarinic activity, which is responsible both for the therapeutic effects of these medications and...
- Mechanism
- Curator reviewed · 1 reference
Mirabegron is a potent and selective agonist of beta-3 adrenergic receptors. The activation of beta-3 receptors relaxes detrusor smooth muscle during the storage phase of the urinary bladder fill-void cycle, which increases the bladder's storage capacity thereby alleviating feelings of urgency and frequency.
- Primary indication
- Mirabegron is indicated for the treatment of overactive bladder (OAB) - with symptoms of urge urinary incontinence, urgency, and urinary frequency - either alone or in combination with solifenacin.Curator reviewed · 3 structured indications
- Formula / weight
- C21H24N4O2S · 396.506 g/mol (avg)
- First approval
- Canada, 2013 · United States, 2012 · European Union, 2016
- Code names
- YM-178
- Brand names
Resolves to
PBAPPPCECJKMCM-IBGZPJMESA-NSMILESNC1=NC(CC(=O)NC2=CC=C(CCNC[C@H](O)C3=CC=CC=C3)C=C2)=CS1What you can answer from here — as of September 23, 2026
Which drugs share a target with Mirabegron, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account